BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 48,520 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 48,520 shares of the stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $304.35, for a total value of $14,767,062.00. Following the completion of the transaction, the chief executive officer owned 11,698 shares in the company, valued at $3,560,286.30. This represents a 80.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Stock Up 0.9%

Shares of NASDAQ:ONC traded up $2.60 on Tuesday, reaching $306.56. The company had a trading volume of 446,980 shares, compared to its average volume of 275,519. The stock has a market capitalization of $33.64 billion, a P/E ratio of 68.58 and a beta of 0.49. The stock has a 50-day moving average price of $290.24 and a 200 day moving average price of $308.90. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion for the quarter. On average, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds have recently modified their holdings of the business. Capital International Investors grew its stake in shares of BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after acquiring an additional 67,808 shares during the last quarter. Siren L.L.C. boosted its holdings in BeOne Medicines by 1.4% in the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after purchasing an additional 7,010 shares during the period. Morgan Stanley increased its holdings in shares of BeOne Medicines by 23.9% during the 4th quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after purchasing an additional 84,367 shares during the period. Bank of America Corp DE raised its position in shares of BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. lifted its stake in shares of BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after buying an additional 62,470 shares during the period. 48.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on ONC shares. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and dropped their price target for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Royal Bank Of Canada raised their target price on shares of BeOne Medicines from $436.00 to $451.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Citizens Jmp reissued a “market outperform” rating and set a $396.00 target price on shares of BeOne Medicines in a research report on Wednesday, July 1st. Barclays decreased their price target on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Guggenheim raised their price target on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $390.92.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.